Home › Funds › Crocodile Capital Partners GmbH › BNTX
Crocodile Capital Partners GmbH position in BNTX
BIONTECH SE · Health Care
Crocodile Capital Partners GmbH reported holding 17,423 shares of BNTX (BIONTECH SE) in its Q3 2026 13F filing — a position valued at US$1.7M, representing 1.07% of its reported portfolio and ranking #7 among its reported holdings. Crocodile Capital Partners GmbH has disclosed BNTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Crocodile Capital Partners GmbH's BNTX position evolved
Crocodile Capital Partners GmbH first disclosed a stake in BNTX in Q3 2023 at 29,586 shares (US$3.2M). The position peaked in Q3 2024 at 29,586 shares, worth US$3.5M. Across 13 filings, Crocodile Capital Partners GmbH increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 17,423 shares valued at US$1.7M — a reduction of -12,163 shares quarter over quarter.. Notable position changes include a 41% trim in Q3 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 29.59K | $3.21M | New |
| Q4 2023 | 29.59K | $3.12M | Hold |
| Q1 2024 | 29.59K | $2.73M | Hold |
| Q2 2024 | 29.59K | $2.38M | Hold |
| Q3 2024 | 29.59K | $3.51M | Hold |
| Q4 2024 | 29.59K | $3.37M | Hold |
| Q1 2025 | 29.59K | $2.69M | Hold |
| Q2 2025 | 29.59K | $3.15M | Hold |
| Q3 2025 | 29.59K | $2.92M | Hold |
| Q4 2025 | 29.59K | $2.82M | Hold |
| Q1 2026 | 29.59K | $2.82M | Hold |
| Q2 2026 | 29.59K | $2.75M | Hold |
| Q3 2026 | 17.42K | $1.71M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BNTX and 13F data
BNTX (BIONTECH SE) is a Health Care company. 35 other funds we track also report a position in BNTX — the largest reported positions include FLOSSBACH VON STORCH SE (US$207.1M), Temasek Holdings (Private) Ltd (US$140.1M), Logos Global Management LP (US$94.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BNTX
- FLOSSBACH VON STORCH SE 2.23M sh · $207.14M · Q2 2026
- Temasek Holdings (Private) Ltd 1.51M sh · $140.14M · Q2 2026
- Logos Global Management LP 1.01M sh · $94.45M · Q2 2026
- GSK plc 889.82K sh · $82.80M · Q2 2026
- Davern Capital Partners, LP 754.55K sh · $70.21M · Q2 2026
- Long Focus Capital Management, LLC 624.00K sh · $58.06M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 470.00K sh · $43.73M · Q2 2026
More on Crocodile Capital Partners GmbH
FAQ
How long has Crocodile Capital Partners GmbH held BNTX?
Crocodile Capital Partners GmbH has disclosed BNTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Crocodile Capital Partners GmbH's current position in BNTX?
As of Q3 2026, Crocodile Capital Partners GmbH holds 17.42K shares of BNTX (BIONTECH SE), valued at $1.71M, representing 1.07% of its reported portfolio and ranking #7.
Has Crocodile Capital Partners GmbH been buying or selling BNTX?
In the latest 13F filing (Q3 2026), Crocodile Capital Partners GmbH reduced its position in BNTX. The position peaked in Q3 2024 at 29.59K shares.
Which other funds hold BNTX?
Other major institutional holders of BNTX include FLOSSBACH VON STORCH SE, Temasek Holdings (Private) Ltd, Logos Global Management LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.